Valuation
- Market cap
- 45,606,000
- Revenue TTM
- $60,000
- Net income TTM
- $-49,820,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -83,033.33%
- Debt to equity
- -0.96
Trading
- Volume
- 4,643,500
- Avg volume
- 5,496,708
- Day's range
- $10.70 – $17.18
- Shares out
- 2,883,000
- Stochastic %K
- 90%
- Beta
- 2.47
- Analysts
- Hold
- Price target
- $2.00
Company profile
Eyenovia, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limi...
Show more
Eyenovia, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi; and agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 917 289 1117
- Website
- https://www.eyenovia.com
- Address
- 295 Madison Avenue, Suite 2400, New York, United States
Latest news
No headlines yet.
